XML 45 R31.htm IDEA: XBRL DOCUMENT v3.25.2
Note 2 - Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Revenues $ 59,543 $ 58,170
Consumables [Member] | Transferred at Point in Time [Member]    
Revenues 35,773 33,010
Hardware and Software [Member] | Transferred at Point in Time [Member]    
Revenues 12,569 14,075
Service [Member] | Transferred at Point in Time [Member]    
Revenues 11,201 11,085
Operating Segments [Member] | Sterilization and Disinfection Control [Member]    
Revenues [1] 25,410 [2] 22,957 [3]
Operating Segments [Member] | Biopharmaceutical Development [Member]    
Revenues [1] 11,486 12,008
Operating Segments [Member] | Calibration Solutions [Member]    
Revenues [1] 12,350 11,801
Operating Segments [Member] | Clinical Genomics [Member]    
Revenues [1] 10,297 11,404
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]    
Revenues 23,011 [2] 20,396 [3]
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]    
Revenues 3,836 3,922
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]    
Revenues 841 580
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]    
Revenues 8,085 8,112
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]    
Revenues 89 [2] 169 [3]
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]    
Revenues 4,288 4,837
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]    
Revenues 6,975 6,886
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]    
Revenues 1,217 2,183
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]    
Revenues 2,310 [2] 2,392 [3]
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]    
Revenues 3,362 3,249
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]    
Revenues 4,534 4,335
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]    
Revenues $ 995 $ 1,109
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals. Revenues as presented are consistent with GAAP measurement principles and our CODM's review of segment information.
[2] Revenues of $24,815 from GKE are included in the Sterilization and Disinfection Control division during the year ended March 31, 2025.
[3] Revenues of $9,289 from GKE are included in the Sterilization and Disinfection Control division during the year ended March 31, 2024 and represent sales made beginning from the acquisition date.